C9ORF72

In one line: A six-letter sequence that repeats hundreds of times in one gene causes the most common inherited form of both ALS and frontotemporal dementia — and a three-pronged mechanism that has so far defeated every attempt to treat it.

---

The gene

C9ORF72 (chromosome 9 open reading frame 72, Gene ID 203228) sits at 9p21.2 on the short arm of chromosome 9. Its protein contains a DENN domain that acts as a guanosine exchange factor (GEF) for a family of small GTPases called Rabs, and it forms a complex (with SMCR8 and WDR41) that helps recruit the ULK1 autophagy initiation complex. In plain language: C9ORF72 helps cells run their internal recycling system. When the protein is absent or reduced, autophagy slows and damaged components accumulate.

But the gene is not famous for its protein. It is famous for what sits in its first intron: a hexanucleotide repeat sequence, GGGGCC, whose copy number varies enormously between individuals.

The mutation

In healthy people, the GGGGCC repeat is present 2–10 times (the large majority of the population has fewer than 10 copies; up to ~23 copies has been observed without pathology). More than 30 copies is considered pathogenic. In patients with ALS or frontotemporal dementia who carry the expansion, the repeat typically runs to 700–1600 copies or more — sometimes several thousand. Detecting these expansions requires a specific PCR method (repeat-primed PCR) designed to catch sequences that loop back on themselves; standard sequencing misses them entirely, which is why the mutation went undetected for so long.

The hunt

By the late 2000s, geneticists had mapped a major ALS/FTD susceptibility locus to chromosome 9p21 through linkage studies of large affected families, but fine-mapping found nothing — no mutations, no obvious structural variants. Two independent teams spent years chasing it. On October 20, 2011, both published simultaneously in Neuron:

• DeJesus-Hernandez et al. (Mayo Clinic), Neuron 72(2):245–256 (PMID 21944778; PMC3202986)
• Renton et al. (an international consortium), Neuron 72(2):257–268 (PMID 21944779; PMC3200438)

Both found the same GGGGCC repeat expansion in C9ORF72. It was, at the time, the largest genetic contribution to a common adult-onset neurodegenerative disease ever identified in a single variant.

The mechanism

What makes C9ORF72 distinctive — and therapeutically difficult — is that the expansion does not act through one mechanism. It acts through three, simultaneously:

1. Loss of function. The expansion partially suppresses C9ORF72 transcription, reducing the protein's expression. Impaired autophagy means damaged proteins and organelles clear more slowly from neurons.

2. RNA foci. The expanded repeat RNA folds into stable G-quadruplex structures and accumulates in the nucleus as dense foci. These foci sequester RNA-binding proteins (RBPs) that the cell needs to splice and export its transcripts, causing widespread downstream disruption of RNA metabolism.

3. Dipeptide-repeat (DPR) proteins via RAN translation. The repeat is translated in both sense and antisense directions without a conventional AUG start codon — a process called repeat-associated non-ATG (RAN) translation, first described for C9ORF72 in 2013 (Ash et al., Science PMID 23959777; Mori et al., Science PMID 23393558). Five DPR species are produced: poly-GA, poly-GR, poly-PR, poly-PA, and poly-GP. The arginine-rich ones — poly-GR and poly-PR — are especially toxic, disrupting nucleocytoplasmic transport, phase-separated condensates, and mitochondrial function.

Which brain regions are most affected determines the clinical presentation: if motor neurons of the spinal cord and brainstem fail first, the patient develops ALS; if neurons of the frontal and temporal cortex fail first, they develop FTD; many patients develop features of both (ALS-FTD). The same expansion, different downstream targets — which is unusual even among neurodegeneration genes.

The stakes

C9ORF72 is the most common known genetic cause of ALS (~40% of familial ALS, ~8% of all ALS) and of frontotemporal dementia (~25% of familial FTD, ~6% of sporadic FTD). It is, in frequency, the dominant genetic driver of two of the most prevalent and devastating adult-onset neurodegenerative conditions.

For carriers identified before symptoms, the question is purely one of time: penetrance is high but not complete, and age of onset varies widely (typically 40s–70s). There is currently no way to predict which disease a carrier will develop, or when.

The frontier

The therapeutic approach that has advanced furthest is RNA targeting: antisense oligonucleotides (ASOs) engineered to bind the repeat-containing transcripts and trigger their degradation. Two programmes reached human trials:

• BIIB078 (Biogen / Ionis Pharmaceuticals): an ASO targeting the sense-strand transcript. Phase 1 study in ALS patients (2022): well-tolerated; reduced dipeptide-repeat proteins in CSF. But clinical measures showed no benefit — and at higher doses, a trend toward faster decline. Development discontinued.

• WVE-004 (Wave Life Sciences): an ASO targeting the aberrant repeat-containing transcript. FOCUS-C9 Phase 1b/2a: achieved 48–50% reduction in poly(GP) DPR in CSF (a clean biomarker hit). But again, no clinical benefit on ALSFRS-R functional scale. Discontinued.

These failures illustrate the central challenge: the mechanism runs three ways. Silencing one arm of a three-pronged disease has not been sufficient. Next-generation strategies under investigation include approaches that simultaneously address loss of function and gain-of-function toxicity, direct targeting of the DPR proteins (particularly poly-GR and poly-PR), restoration of nucleocytoplasmic transport, and combinatorial ASO strategies.

No treatment yet changes the course of C9ORF72-associated ALS or FTD.

Sources

Full claim-by-claim evidence is in references.md. Primary anchors:

• DeJesus-Hernandez et al. 2011 — PMC3202986
• Renton et al. 2011 — PMID 21944779
• GeneReviews: C9ORF72 — NBK268647
• C9ORF72 protein / autophagy — PMC6829620
• Ash et al. 2013 (DPR proteins) — PMID 23959777
• Mori et al. 2013 (RAN translation) — PMID 23393558
• NCBI Gene C9ORF72 (203228)

Accuracy note: Two ⚠️ traps in this episode. (1) The normal repeat range: narration says "2 to 10" — conservative and correct for the vast majority; healthy individuals can carry up to ~23 repeats, and the precise pathogenic threshold (~30+) is noted in references.md. (2) The ASO trial failures: BIIB078 and WVE-004 were Phase 1 / Phase 1b trials, not powered for definitive efficacy — the failure is informative but the interpretation requires care. Narration states only "the disease didn't slow," which is accurate.